COMPARE · Data as of August 21, 2026
INDV vs LLY
Verdict: Side-by-side breakdown using the Bull Rankings model. INDV scored 63.0, LLY scored 69.8 — LLY leads.
Compare another set
INDV
Indivior Pharmaceuticals, Inc.
63
$36.87 · $4.4B
fundamentals as of
Score gap
6.8
LLY leads
LLY
Eli Lilly and Company
69.8
$1,255.40 · $1.1T
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthLLY+49.6%
- Highest qualityLLY73 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
INDV
stronger →← stronger
LLY
50
Qualityreturns · margins · balance sheet
73
87
Growthrevenue & earnings expansion
97
57
Valuevaluation vs sector peers
48
LLY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
INDV
LLY
-$111mF
FCF
$13.6bA-
+13.5%B+
Rev
+49.6%A
—
D/E
1.62C
3.3xB+
P/S
—
1.26B
PEG
1.61C+
—
P/E
42.2xC
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
INDV
LLY
—
Price vs fair valuelower is cheaper
113% above
—
Growth the price implies10-yr FCF · lower = less priced in
~33%/yr
—
1-yr DCF upside
-65%
—
5-yr DCF upside
-53%
—
10-yr DCF upside
-27%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
INDV
Why this score
- Buying back stock
LLY
Why this score
- Raising its dividend
The companies
INDVIndivior Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $4.4b. 14% off the 52-week high of $42.81. Revenue growing +13%, comfortably above the S&P median. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $49.00 (implying +33% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$111m) — capital raises or debt issuance likely required; dilution / leverage risk. ROE -171% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
LLYEli Lilly and Company
Why now
Drug Manufacturers - General · market cap $1.1T. Trading near 52-week high of $1292.65 — momentum setup, limited technical margin of safety. Revenue growing +50% — in hypergrowth territory. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $1,311 (implying +4% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 42x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 14.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where INDV and LLY diverge
On the headline score the gap is 6.8 points in favor of LLY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityINDV 49.9 · LLY 73.0LLY +23.1
- GrowthINDV 87.2 · LLY 97.0LLY +9.8
- ValueINDV 57.5 · LLY 47.9INDV +9.6
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.